15 Jun 2026 | Press release
We are pleased to share an important milestone for Technophage: the Phase 1/2a clinical study TP-122_101A has recently received the necessary regulatory approvals to move forward in Europe, specifically Portugal and the Netherlands. The study, entitled...
22 Dez 2025 | Press release
We are pleased to share that last Friday marked an important milestone for Technophage with the End of Study of the TP-102 Phase 2b clinical trial. We would like to sincerely thank our CRO partners, Principal Investigators, and hospital teams in the United States and...
30 Jan 2025 | Press release
TECHNOPHAGE, a Portuguese company specializing in GMP phage development and PHAXIAM Therapeutics, a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, announce today its intent to establish a strategic...
9 Fev 2024 | Press release
Technophage, a biopharmaceutical company specializing in the development and production of biologics, particularly bacteriophage-based products, has officially announced the successful dosing of the first patient in this pivotal stage. The trial aims to assess the...
14 Dez 2023 | Press release
TechnoPhage, a clinical-stage biopharmaceutical company specializing in the development of phage treatments targeting specific pathogenic bacteria, has announced, following the successful conclusion of the Phase 1 study in 2022, the initiation of Phase 2b study...
4 Abr 2023 | Press release
Technophage is one of the co-promoters of the Bio-Hub Agenda – a National R&D Platform for Production, Commercialization and Distribution of Innovative Biopharmaceuticals – together with LxBio – Pharmaceuticals, VectorB2B – Drug...
